| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.YGYNO.2007.03.021 |
| P698 | PubMed publication ID | 17481705 |
| P50 | author | Laura J. Havrilesky | Q87009294 |
| Angeles Alvarez Secord | Q87010814 | ||
| Kathleen M Darcy | Q91542616 | ||
| Alan D Hutson | Q92074799 | ||
| Andrew Berchuck | Q114258102 | ||
| Lisa A Grace | Q114338161 | ||
| P2093 | author name string | Paula S Lee | |
| Gynecologic Oncology Group study | |||
| P2860 | cites work | Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1 | Q24672489 |
| Nonparametric Estimation from Incomplete Observations | Q25938997 | ||
| Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats | Q28145149 | ||
| Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene | Q29547732 | ||
| Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele | Q29547733 | ||
| Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components | Q33245035 | ||
| Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study | Q33331105 | ||
| Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G | Q33335882 | ||
| Clinical applications of angiogenic growth factors and their inhibitors | Q33784288 | ||
| Antiangiogenic agents and their promising potential in combined therapy | Q34288928 | ||
| Thrombospondin-1 and cutaneous melanoma | Q35007157 | ||
| Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors | Q35690266 | ||
| Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas | Q35746653 | ||
| Expression of vascular endothelial growth factor and p53 in pancreatic carcinomas | Q35937409 | ||
| The role of vascular endothelial growth factor (VEGF) and p53 status for angiogenesis in gastric cancer | Q35937469 | ||
| Thrombospondin modulates alpha v beta 3 function through integrin-associated protein | Q36237547 | ||
| CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells | Q36276395 | ||
| Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels | Q36431375 | ||
| Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer | Q41195958 | ||
| Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis | Q43517650 | ||
| Influence of intratumoral basic fibroblast growth factor concentration on survival in ovarian cancer patients. | Q43648619 | ||
| The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma | Q43943699 | ||
| The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma | Q44103449 | ||
| The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. | Q46365760 | ||
| Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression | Q46439216 | ||
| Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. | Q47290049 | ||
| Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer | Q48035577 | ||
| Immunohistochemical expression of thrombospondin-1 in invasive vulvar squamous cell carcinoma. | Q53356377 | ||
| The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer. | Q53358645 | ||
| Vascular endothelial growth factor expression in early stage ovarian carcinoma | Q53359012 | ||
| Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations. | Q53394047 | ||
| Thrombospondin-induced attachment and spreading of human squamous carcinoma cells. | Q55487458 | ||
| On the Interpretation of χ 2 from Contingency Tables, and the Calculation of P | Q55893855 | ||
| A Network Algorithm for Performing Fisher's Exact Test in r × c Contingency Tables | Q56432190 | ||
| The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells | Q60043731 | ||
| Expression of Thrombospondin-1 in Resected Colorectal Liver Metastases Predicts Poor Prognosis | Q61812675 | ||
| Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells | Q71067440 | ||
| Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1 | Q71644976 | ||
| Thrombospondin (TSP) and transforming growth factor beta 1 (TGF-beta) promote human A549 lung carcinoma cell plasminogen activator inhibitor type 1 (PAI-1) production and stimulate tumor cell attachment in vitro | Q72207136 | ||
| Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines | Q72721355 | ||
| Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas | Q73032228 | ||
| Thrombospondin-1 expression in oral squamous cell carcinomas: correlations with tumor vascularity, clinicopathological features and survival | Q73088776 | ||
| Ovarian cancer p53 mutation is associated with tumor microvessel density | Q74342961 | ||
| Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice | Q74376048 | ||
| Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients | Q74448972 | ||
| Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: in association with transforming growth factor beta and vascular endothelial growth factor | Q75421892 | ||
| Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma | Q77900424 | ||
| Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer | Q77947354 | ||
| Prognostic Significance of p53 Mutation and p53 Overexpression in Advanced Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study | Q79150763 | ||
| Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancers | Q80944044 | ||
| Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival | Q81829697 | ||
| Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma | Q82723129 | ||
| P433 | issue | 1 | |
| P921 | main subject | gynecologic oncology | Q5625186 |
| ovarian cancer | Q172341 | ||
| P304 | page(s) | 221-232 | |
| P577 | publication date | 2007-05-03 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study | |
| P478 | volume | 106 |
| Q53370060 | Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology G |
| Q39524316 | BMP-4 expression has prognostic significance in advanced serous ovarian carcinoma and is affected by cisplatin in OVCAR-3 cells |
| Q33781661 | Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines |
| Q42433614 | Expression and clinical significance of vascular endothelial growth factor and fms-related tyrosine kinase 1 in colorectal cancer |
| Q34648726 | Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells |
| Q53424963 | Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study. |
| Q90862808 | Jumonji domain-containing 6 (JMJD6) identified as a potential therapeutic target in ovarian cancer |
| Q26830493 | Metronomic therapy for gynecologic cancers |
| Q30497303 | Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer |
| Q37328373 | Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies |
| Q44402598 | Prognostic impact of VEGF and FLT-1 receptor expression in patients with locally advanced squamous cell carcinoma of the head and neck. |
| Q54676836 | Prognostic impact of VEGF and VEGF receptor 1 (FLT1) expression in patients irradiated for stage II/III non-small cell lung cancer (NSCLC). |
| Q37383301 | S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013. |
| Q39776334 | Similar expression profiles of a core of genes and proteins in cells that have acquired a metastatic phenotype, genetically or by in vivo evolution |
| Q37261697 | TP53 Status is Associated with Thrombospondin1 Expression In vitro |
| Q38058991 | The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis. |
| Q36571442 | The relationship of the angiogenesis regulators VEGF-A, VEGF-R1 and VEGF-R2 to p53 status and prognostic factors in epithelial ovarian carcinoma in FIGO-stages I-II. |
| Q33880468 | Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies |
| Q39598551 | Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer |
| Q54636428 | Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors |
| Q36414088 | Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer |
Search more.